1. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

    New England Journal of Medicine 366(20):1870 (2012) PMID 22591293

    Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to anti-JC virus antibodies, prior use of immunos...
  2. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

    Annals of Neurology 70(5):742 (2011) PMID 22162056

    A study was undertaken to define the prevalence of anti-JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false-negative rate of a 2-step anti-JC virus antibody assay. STRATIFY-1 is an ongoing, longitudinal, observational study of relapsing MS patients ...
  3. Anti-JC virus antibodies: implications for PML risk stratification.

    Annals of Neurology 68(3):295 (2010) PMID 20737510

    A study was undertaken to establish an enzyme-linked immunosorbent assay (ELISA) to detect JC virus (JCV)-specific antibodies in multiple sclerosis (MS) patients, and to evaluate its potential utility for identifying patients at higher or lower risk (ie, risk stratification) of developing progre...
  4. Reply: To PMID 19798640.

    Annals of Neurology 67(2):271 (2010) PMID 20225308

  5. LINGO-1 and its role in CNS repair

    The International Journal of Biochemistry & Cel... 40(10):1971 (2008) PMID 18468478

    LINGO-1 is selectively expressed in the CNS on both oligodendrocyte precursor cells (OPCs) and neurons. Its expression is developmentally regulated in the normal CNS, as well as up-regulated in human or rat models of neuropathologies. LINGO-1 functions as a negative regulator of oligodendro...
  6. LINGO-1 and its role in CNS repair

    The International Journal of Biochemistry & Cel... 40(10):1971 (2008) PMID 18468478

    LINGO-1 is selectively expressed in the CNS on both oligodendrocyte precursor cells (OPCs) and neurons. Its expression is developmentally regulated in the normal CNS, as well as up-regulated in human or rat models of neuropathologies. LINGO-1 functions as a negative regulator of oligodendro...
  7. Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis

    Clinical Immunology 119:S116 (2006)

  8. Natalizumab and progressive multifocal leukoencephalopathy.

    New England Journal of Medicine 353(4):432 (2005) PMID 15947083

  9. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

    Expert Review of Neurotherapeutics 4(4):571 (2004) PMID 15853576

    Natalizumab (Antegren, Elan Corp. plc.; Biogen Idec.) is the first alpha4-integrin antagonist in the class of selective adhesion molecule inhibitors and is in Phase III clinical trials for the treatment of multiple sclerosis. After a 300 mg intravenous infusion, natalizumab has an elimination ha...
  10. The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004.

    Journal of Neuroimmunology 152(1-2):1 (2004) PMID 15303274

  11. The blood–brain barrier as target of multiple sclerosis research and therapy:Report of an international scientific meeting, Würzburg, January 23/24, 2004

    Journal of Neuroimmunology 152(1):1 (2004)